| Nov 8 |
Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
|
| Nov 8 |
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma
|
| Nov 8 |
Moderna Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 8 |
Moderna Inc (MRNA) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ...
|
| Nov 7 |
Pfizer, GSK, Moderna struggle in a shrinking RSV vaccine market
|
| Nov 7 |
Moderna (MRNA) Q3 2024 Earnings Call Transcript
|
| Nov 7 |
Moderna Stock Rises on Q3 Earnings & Sales Beat, Reiterates View
|
| Nov 7 |
Moderna Stock Rises on Surprise Q3 Profit
|
| Nov 7 |
Moderna Gets Third-Quarter Boost From Early COVID-19 Shot Approval as Sales Top Street Views
|
| Nov 7 |
2025 will be 'fairly challenging year' for Moderna: Analyst
|
